Signature Estate & Investment Advisors LLC Purchases New Holdings in Stryker Co. (NYSE:SYK)

Signature Estate & Investment Advisors LLC acquired a new position in shares of Stryker Co. (NYSE:SYK) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 1,404 shares of the medical technology company’s stock, valued at approximately $478,000.

A number of other institutional investors have also modified their holdings of the stock. St. Johns Investment Management Company LLC grew its holdings in shares of Stryker by 2.1% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 5,129 shares of the medical technology company’s stock worth $1,745,000 after acquiring an additional 107 shares during the period. SlateStone Wealth LLC acquired a new stake in Stryker in the second quarter valued at $684,000. Bailard Inc. increased its position in shares of Stryker by 127.5% in the second quarter. Bailard Inc. now owns 25,264 shares of the medical technology company’s stock valued at $8,596,000 after buying an additional 14,157 shares in the last quarter. Verdence Capital Advisors LLC raised its stake in shares of Stryker by 20.6% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,353 shares of the medical technology company’s stock worth $460,000 after buying an additional 231 shares during the last quarter. Finally, Catalyst Financial Partners LLC boosted its position in shares of Stryker by 5.3% in the 2nd quarter. Catalyst Financial Partners LLC now owns 1,402 shares of the medical technology company’s stock worth $477,000 after buying an additional 70 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on SYK shares. Wells Fargo & Company lifted their target price on shares of Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. UBS Group boosted their price target on Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Morgan Stanley boosted their target price on shares of Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Roth Mkm raised their price target on shares of Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $373.11.

Stryker Trading Up 1.2 %

NYSE SYK opened at $358.51 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The firm has a market capitalization of $136.62 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 2.74 and a beta of 0.89. The company’s 50 day moving average price is $336.10 and its 200 day moving average price is $341.09. Stryker Co. has a one year low of $249.98 and a one year high of $361.41.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The company had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 earnings per share. On average, sell-side analysts predict that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s payout ratio is 36.53%.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the completion of the transaction, the director now owns 3,316,608 shares in the company, valued at $1,072,790,023.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at $3,219,495. The disclosure for this sale can be found here. Insiders sold a total of 210,600 shares of company stock valued at $68,330,400 in the last ninety days. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.